HC Wainwright Brokers Lift Earnings Estimates for Precigen

Precigen, Inc. (NASDAQ:PGEN) – Equities researchers at HC Wainwright increased their FY2026 EPS estimates for Precigen in a research report issued to clients and investors on Thursday, May 14th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of $0.02 for the year, up from their prior estimate of ($0.02). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Precigen’s current full-year earnings is $0.02 per share. HC Wainwright also issued estimates for Precigen’s FY2027 earnings at $0.34 EPS.

Precigen (NASDAQ:PGEN) last released its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. Precigen had a negative net margin of 646.99% and a positive return on equity of 717.50%. The company had revenue of $23.25 million during the quarter, compared to analyst estimates of $20.81 million.

A number of other equities analysts have also commented on PGEN. Wall Street Zen upgraded shares of Precigen from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Citigroup restated an “outperform” rating on shares of Precigen in a research report on Thursday. Citizens Jmp raised their price objective on shares of Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a research report on Thursday, May 14th. Zacks Research upgraded shares of Precigen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Precigen presently has a consensus rating of “Hold” and a consensus price target of $11.00.

Precigen Price Performance

PGEN stock opened at $4.07 on Tuesday. The firm has a 50 day moving average of $3.87 and a 200-day moving average of $4.08. The company has a current ratio of 4.82, a quick ratio of 4.12 and a debt-to-equity ratio of 4.62. Precigen has a 12 month low of $1.28 and a 12 month high of $5.47. The firm has a market capitalization of $1.45 billion, a P/E ratio of -3.45 and a beta of 1.07.

Institutional Investors Weigh In On Precigen

Hedge funds have recently bought and sold shares of the stock. State of Wyoming bought a new stake in Precigen during the first quarter valued at approximately $27,000. NBC Securities Inc. bought a new stake in shares of Precigen in the 4th quarter worth approximately $38,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Precigen in the 3rd quarter worth approximately $39,000. Royal Bank of Canada lifted its holdings in shares of Precigen by 102.6% in the 1st quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 5,426 shares during the last quarter. Finally, Russell Investments Group Ltd. bought a new stake in shares of Precigen in the 3rd quarter worth approximately $41,000. 33.51% of the stock is currently owned by institutional investors.

Insider Transactions at Precigen

In other Precigen news, Director Randal J. Kirk sold 4,772,781 shares of Precigen stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $3.30, for a total transaction of $15,750,177.30. Following the completion of the sale, the director directly owned 302,213 shares in the company, valued at $997,302.90. The trade was a 94.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 47.10% of the stock is currently owned by insiders.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.